{
    "clinical_study": {
        "@rank": "97461", 
        "arm_group": [
            {
                "arm_group_label": "Quinvaxem in Uniject", 
                "arm_group_type": "Experimental", 
                "description": "A single dose (0.5 mL) of Quinvaxem contains:\ndiphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen\nOne dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device"
            }, 
            {
                "arm_group_label": "Quinvaxem in single dose vials", 
                "arm_group_type": "Active Comparator", 
                "description": "A single dose (0.5 mL) of Quinvaxem contains:\ndiphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen\nOne dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to show that vaccination with three doses of Quinvaxem presented in Uniject\n      is not inferior to vaccination with three doses of Quinvaxem presented in single dose vials,\n      with respect to protection against all antibodies (anti-hepatitis B surface antibodies,\n      anti-polyribosyl ribitol phosphate (PRP), anti-diphtheria, anti-tetanus and anti-Bordetella\n      pertussis) one (1) month after completion of the 6-10-14 week vaccination course."
        }, 
        "brief_title": "A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diphtheria", 
            "Pertussis", 
            "Tetanus", 
            "Hepatitis B", 
            "Haemophilus Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diphtheria", 
                "Haemophilus Infections", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Whooping Cough", 
                "Tetanus", 
                "Tetany"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A male or female between, and including, 42 and 64 days of age at the time of the\n             first vaccination\n\n          -  Written informed consent obtained from parents/legal guardians of the subject\n\n          -  Free of obvious health problems as established by medical history and/or clinical\n             examination before entering the study\n\n          -  HepB vaccination at birth (within 48 hours)\n\n          -  Available for all scheduled study visits\n\n        Exclusion Criteria:\n\n          -  Use of any investigational drug or any investigational vaccine in the 30 days\n             preceding the first dose of study vaccine, or their planned use during the study\n             period and safety follow-up\n\n          -  Planned administration of a vaccine not foreseen by the Study Protocol\n\n          -  Known or suspected impairment of immune function, known HIV-positivity; actively\n             receiving immunosuppressive therapy, or in receipt of systemic immunosuppressive\n             therapy in the one month prior to study entry (note: inhaled and topical steroids are\n             allowed)\n\n          -  Administration of parenteral immunoglobulin preparation and/or blood products since\n             birth\n\n          -  Previous vaccination against Hib and/or DTP\n\n          -  History of anaphylaxis, or any serious vaccine reaction, or hypersensitivity to any\n             vaccine component or to products containing mercury compounds, such as thiomersal\n\n          -  Clinically significant acute infection\n\n          -  Clinically significant acute illness\n\n          -  Any condition that, in the opinion of the investigator, might interfere with the\n             evaluation of the study objectives\n\n          -  Participation in another clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Days", 
            "minimum_age": "42 Days"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917357", 
            "org_study_id": "QVX-V-D001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Quinvaxem in Uniject", 
                "intervention_name": "Quinvaxem in Uniject", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Quinvaxem in single dose vials", 
                "intervention_name": "Quinvaxem in single dose vials", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vaccination", 
            "Immunisation", 
            "Virus", 
            "Diphtheria", 
            "Pertussis", 
            "Tetanus", 
            "Hepatitis B", 
            "Haemophilus Influenzae", 
            "Immunity"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Muntinlupa City", 
                    "country": "Philippines"
                }, 
                "name": "Research Institute for Tropical Medicine"
            }
        }, 
        "location_countries": {
            "country": "Philippines"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem\u00ae DTwP-HepB-Hib) in Uniject\u2122 With Quinvaxem\u00ae Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age", 
        "overall_official": {
            "affiliation": "Research Institute for Tropical Medicine (RITM)", 
            "last_name": "Maria RZ Capeding, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Philippines: Bureau of Food and Drugs", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Seroprotection Rate: Anti-PRP Antibodies", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third vaccination"
            }, 
            {
                "measure": "Seroprotection Rate: Anti-hepatitis B Surface Antibodies", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third vaccination"
            }, 
            {
                "measure": "Anti-diphtheria Toxoid Antibodies", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third vaccination"
            }, 
            {
                "measure": "Seroprotection Rate: Anti-tetanus Toxoid Antibodies", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third vaccination"
            }, 
            {
                "measure": "Seroprotection Rate: Anti-B. Pertussis Antibodies", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917357"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Crucell Holland BV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Crucell Holland BV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}